Related references
Note: Only part of the references are listed.Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Helen Rizos et al.
CLINICAL CANCER RESEARCH (2014)
Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
Reinhard Dummer et al.
EUROPEAN JOURNAL OF CANCER (2014)
Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
Richard Kefford et al.
Journal of Translational Medicine (2014)
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin et al.
LANCET ONCOLOGY (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
BRAF in Melanoma: Current Strategies and Future Directions
April K. S. Salama et al.
CLINICAL CANCER RESEARCH (2013)
New Challenges in Endpoints for Drug Development in Advanced Melanoma
Antoni Ribas et al.
CLINICAL CANCER RESEARCH (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
Melanoma in the brain: biology and therapeutic options
Geoffrey Thomas Gibney et al.
MELANOMA RESEARCH (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Number of Metastases, Serum Lactate Dehydrogenase Level, and Type of Treatment Are Prognostic Factors in Patients With Brain Metastases of Malignant Melanoma
Thomas K. Eigentler et al.
CANCER (2011)
Prognostic Factors for Survival in Melanoma Patients With Brain Metastases
Michael A. Davies et al.
CANCER (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Determinants of survival in patients with brain metastases from cutaneous melanoma
M. Staudt et al.
BRITISH JOURNAL OF CANCER (2010)
Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy
Jenny J. Hong et al.
CLINICAL CANCER RESEARCH (2010)
Brain metastases: a medical neuro-oncology perspective
Marc C. Chamberlain
EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
Temozolomide, Thalidomide, and Whole Brain Radiation Therapy for Patients With Brain Metastasis From Metastatic Melanoma A Phase II Cytokine Working Group Study
Michael B. Atkins et al.
CANCER (2008)
Temozolomide plus thalidomide in patients with brain metastases from melanoma - A phase II study
WJ Hwu et al.
CANCER (2005)
Determinants of outcome in melanoma patients with cerebral metastases
KM Fife et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study
SS Agarwala et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of maliqnant melanoma
F Mornex et al.
MELANOMA RESEARCH (2003)
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group
K Margolin et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2002)
Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases
LM Guirguis et al.
JOURNAL OF IMMUNOTHERAPY (2002)
Share Paper
